Drug Type Small molecule drug |
Synonyms mangafodipir, Mangafodipir trisodium (USAN), MnDPDP + [9] |
Target- |
Mechanism- |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date EU (22 May 1997), |
Regulation- |
Molecular FormulaC22H25MnN4NaO14P2 |
InChIKeyOFHJWKIWWOCMSS-UHFFFAOYSA-G |
CAS Registry140678-14-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04848 | Mangafodipir Trisodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | EU | 22 May 1997 | |
Contrast agents | IS | 22 May 1997 | |
Contrast agents | LI | 22 May 1997 | |
Contrast agents | NO | 22 May 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiomyopathy, Hypertrophic | Phase 2 | NO | 22 Nov 2024 | |
Heart failure with normal ejection fraction | Phase 2 | NO | 22 Nov 2024 | |
Acute myocardial infarction | Phase 2 | SE | 01 Dec 2009 | |
Stage III Colon Cancer | Phase 2 | SE | 01 Jun 2008 |